Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study

Table 5 Time to venous thromboembolism according to chemotherapeutic agent used for 1^st-line chemotherapy

Variable	Patients (n)	Patients with VTE n (%)	Risk of time to VTE
			HR	95%CI	P value
Fluoropyrimidine
SP	96	11 (11.5)
XP	22	3 (13.6)	1.67	0.47-6.18	0.422
Platinum
XP	22	3 (13.6)
XELOX	27	4 (14.8)	0.94	0.21-4.25	0.94
Addition of targeted agents
Conventional chemotherapy	158	17 (10.8)
+ targeted agents	83	10 (12.0)	1.21	0.56-2.65	0.627
Addition of VEGFR inhibitors
Conventional chemotherapy	217	27 (12.4)
+ VEGFR inhibitors	24	0	0.04	0.00-12.13	0.227

SP: TS-1 + cisplatin; XP: Capecitabine + cisplatin; XELOX: Capecitabine + oxaliplatin, targeted agents, Vorinostat, sorafenib, Bevacizumab, or trastuzumab +/- pertuzumab; VEGFR: Inhibitors, sorafenib or bevacizumab; VTE: Venous thromboembolism.